What is the recommended dose and frequency of metoclopramide (antiemetic medication) for a 12-year-old female?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Metoclopramide Dosing for a 12-Year-Old Female

For a 12-year-old female, administer metoclopramide 0.1 mg/kg IV or IM (maximum 10 mg per dose) every 6-8 hours as needed for nausea and vomiting, with treatment limited to 5 days maximum to minimize serious neurological risks. 1, 2

Weight-Based Pediatric Dosing

  • The standard pediatric dose is 0.1 mg/kg per dose, which can be given intramuscularly or intravenously 1
  • For a typical 12-year-old weighing approximately 40 kg, this translates to 4 mg per dose
  • Maximum single dose should not exceed 10 mg, regardless of calculated weight-based dose 1
  • Dosing frequency should be every 6-8 hours (3-4 times daily maximum) 2, 3

Critical Duration Limitation

Treatment must be restricted to a maximum of 5 days to minimize the risk of extrapyramidal disorders and tardive dyskinesia 2. This is a firm regulatory recommendation from the European Medicines Agency that applies to all age groups, but is particularly important in pediatric patients who have higher susceptibility to neurological adverse effects.

Route of Administration

  • IV or IM routes are preferred in acute settings for reliable absorption and rapid onset 1, 3
  • Oral administration at 5-20 mg per dose can be used if the patient can tolerate oral intake, but should still follow weight-based dosing principles for pediatrics 2, 3

Essential Safety Precautions

High-Risk Adverse Effects in Pediatric Patients

  • Extrapyramidal reactions (EPRs) occur more frequently in children and young adults compared to older adults 4, 5
  • Acute dystonic reactions developed in approximately 38-45% of pediatric patients in studies using higher doses (1-2 mg/kg) 4, 5
  • Akathisia (restlessness) occurred in 33% of children receiving doses ≥2 mg/kg 4

Contraindications

Avoid metoclopramide entirely in patients with: 1, 3

  • Seizure disorders
  • Pheochromocytoma
  • GI bleeding or obstruction
  • Severe renal or hepatic impairment (requires dose adjustment if used)

Monitoring Requirements

  • Watch for dystonic reactions (involuntary movements, muscle spasms, particularly of face, neck, and extremities) which can occur even with low doses 6, 5
  • Monitor for QT prolongation with repeated dosing 1
  • Be prepared to administer diphenhydramine 25-50 mg IV/IM immediately if extrapyramidal symptoms develop 4, 5

Critical Pitfall to Avoid

Do not use consecutive day dosing if possible - children who received metoclopramide on consecutive days had significantly higher rates of extrapyramidal reactions 4. If multi-day treatment is absolutely necessary, consider prophylactic diphenhydramine with each dose 4, 5.

Alternative Consideration

Given the significant neurological risks in pediatric patients, ondansetron may be a safer first-line antiemetic for this age group, with typical dosing of 0.15 mg/kg IV (maximum 8 mg) 7. Reserve metoclopramide for cases where ondansetron has failed or when prokinetic effects are specifically needed (e.g., gastroparesis, severe gastroesophageal reflux) 8.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Metoclopramide Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Metoclopramide Dosage and Administration for Hiccups

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985

Research

Metoclopramide as an antiemetic agent in pediatric oncology patients.

Drug intelligence & clinical pharmacy, 1986

Guideline

Ondansetron Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Metoclopramide: a dopamine receptor antagonist.

American family physician, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.